Bb5a31f81ClaimBipartisan legislation introduced in the United States Congress proposed capping monthly out-of-pocket insulin costs for patients at $35AgreeDisagree
Bb5a31f81ClaimPimavanserin is a selective 5-HT2A inverse agonist medication used to treat Parkinson's disease psychosisAgreeDisagree
Bb5a31f81ClaimIn the 1970s, Dr. Frank Parano of the University of Wisconsin Medical School isolated the glycoprotein RC183 from Cortinarius caperatus, showing activity against herpes virusesAgreeDisagree
Bb5a31f81ClaimMerck and Moderna developed an experimental melanoma vaccine and planned to seek approval from the United States Food and Drug AdministrationAgreeDisagree
Bb5a31f81ClaimDapagliflozin is an FDA-approved SGLT2 inhibitor marketed under the brand name FarxigaAgreeDisagree
Bb5a31f81ClaimCanagliflozin is an FDA-approved SGLT2 inhibitor marketed under the brand name InvokanaAgreeDisagree
Bb5a31f81ClaimEmpagliflozin is an FDA-approved SGLT2 inhibitor marketed under the brand name JardianceAgreeDisagree
Bb5a31f81ClaimAs of November 2026, the average development cost of a new drug has risen to approximately 1.5 billion dollarsAgreeDisagree
Bb5a31f81ClaimDeveloping a new drug traditionally takes approximately 15 years from initial discovery to regulatory approvalAgreeDisagree
Bb5a31f81ClaimDrug regulatory frameworks historically mandated testing candidate molecules on rats and other animals before human clinical trialsAgreeDisagree
Bb5a31f81ClaimDespite an expansion in biomedical literature and drug modalities, the annual number of new drug approvals has remained roughly flatAgreeDisagree
Bb5a31f81ClaimRevolution Medicines developed the KRAS inhibitor daraxonrasib to treat late-stage pancreatic cancer patientsAgreeDisagree
Bb5a31f81ClaimApproximately 10% of experimental drug candidates successfully pass clinical trialsAgreeDisagree
Bb5a31f81ClaimAntisense oligonucleotides are short RNA molecules designed to bind target RNA transcripts to modify splicing or gene expressionAgreeDisagree
Bb5a31f81ClaimGLP-1 receptor agonist medications suppress appetite by targeting neural signaling pathways that regulate hunger and body weight settling pointsAgreeDisagree
Bb5a31f81ClaimApproximately 50% to 60% of patients prescribed GLP-1 receptor agonist medications discontinue treatment within a few yearsAgreeDisagree
Bb5a31f81ClaimRapid weight loss from GLP-1 receptor agonists often includes substantial reductions in skeletal muscle mass alongside fat lossAgreeDisagree
Bb5a31f81ClaimMore than 20 pharmaceutical companies reached agreements with the Trump administration pledging not to charge significantly higher drug prices in the United States than in other nationsAgreeDisagree
Bb5a31f81ClaimBayer co-markets a blood-thinner medication with Johnson & Johnson that faces generic market competitionAgreeDisagree